Actively Recruiting

Phase Not Applicable
All Genders
NCT04681534

Safety and Efficacy of Adaptive Deep Brain Stimulation

Led by Newronika · Updated on 2024-07-09

15

Participants Needed

8

Research Sites

257 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to assess the safety and the potential efficacy of personalized Local Field Potential (LFP)-based adaptive Deep Brain Stimulation (aDBS), using the implantable pulse generator (IPG) of the "AlphaDBS" System, in Parkinson's Disease patients, chronically implanted in subthalamic nucleus (STN) for DBS.

CONDITIONS

Official Title

Safety and Efficacy of Adaptive Deep Brain Stimulation

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of idiopathic Parkinson's Disease
  • Bilateral DBS treatment in the subthalamic nucleus with specific Medtronic IPGs for at least 3 years needing battery replacement within 12 months
  • Ability to understand and sign informed consent
  • Age 18 years or older
  • Diagnosed with levodopa-responsive idiopathic Parkinson's disease for 5 years or more
  • Disease stage II, III, or IV on Hoehn and Yahr scale
  • History of symptom improvement with levodopa
  • Selected for bilateral STN or GPi DBS with specified leads
  • DBS lead circuit integrity confirmed before IPG implantation
  • MoCA score above 26 in best medical condition
  • BDI-II score below 17 in best medical condition
  • UPDRS-III improvement by at least 33% with levodopa challenge test
  • Ability to understand study requirements and provide informed consent
  • Responsible caregiver available to assist with diaries and compliance
  • Stable Parkinson's medication for one month before surgery
  • Willingness and ability to attend all study visits and follow procedures
Not Eligible

You will not qualify if you...

  • Severe cognitive decline with MoCA score less than 10
  • Major psychiatric issues or conditions interfering with study conduct
  • Medical conditions interfering with DBS battery replacement surgery
  • Need to replace or reposition leads during IPG replacement
  • More than 10 recurrent falls in 3 months prior to consent
  • Inability to tolerate interruption of DBS for at least 30 minutes
  • Taking less than one levodopa dose per day
  • Unsuitable local field potential recordings or significant artifacts
  • Pregnant or breastfeeding women
  • Contraindications for DBS surgery including intracranial abnormalities or metallic implants
  • History of suicide attempt or active suicidal thoughts
  • Dementia, major depression, seizures, congestive heart failure, uncontrolled diabetes, dialysis, substance use disorders, or other severe medical conditions
  • Conditions interfering with study procedures or data collection
  • Terminal illness with survival less than 12 months
  • Need for repeated MRI scans
  • Requirement for diathermy, transcranial magnetic stimulation, or electroconvulsive therapy
  • Presence of electrical or electromagnetic implants
  • Use of implanted electrical stimulation devices or medication pumps
  • Anticoagulant therapy that cannot be paused for more than 5 days before surgery
  • History of cranial surgery for Parkinson's treatment
  • Participation in another clinical study
  • Female participants who are breastfeeding, pregnant, or not using adequate contraception

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

Actively Recruiting

2

IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

Completed

3

Azienda Ospedale Universitario di Padova - Università di Padova

Padova, Italy

Withdrawn

4

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy

Completed

5

AOU Città della Salute e della Scienza di Torino

Turin, Italy

Completed

6

Maastricht Medical Center

Maastricht, Netherlands

Withdrawn

7

Copernicus Podmiot Leczniczy

Gdansk, Poland

Withdrawn

8

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

Warsaw, Poland

Completed

Loading map...

Research Team

C

Costanza Conti, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here